The phase 2 trial was approved early in 2017, so it will be 5 years by the time they get one going.
Not sure what data you're referring to, but I'd expect with a viable product that could be proven and then sold commercially (ie - the price of the eventual treatment wouldn't be so high that the insurance companies would balk but would generate a profit), someone in biotech land would have funded it over those 5 years, OTC or not. Heck, they worked with Pfizer for awhile, deep pockets there. Nobody did, though.
But that's OK, they can get started with it now, and if they can manage their money better, maybe sell a little more stock, they'll finish. I think I read the trial is 1-2 years, then there'll be other trials to follow.
My remarks addressed what NASDAQ "sees" relative to the comment about biotechs being worth $250M market cap. This company will have to prove itself and hasn't, especially considering the recent bankruptcy and the 5 year old FDA trial approval.
Market Data 
Markets 
AI
